Efficacy and Safety of Intra-arterial Administration of REX-001 in the Treatment of Ischemic Ulcers in Patients With Rutherford Category 5 Potentially Dangerous Lower Extremity Chronic Ischemia and Diabetes Mellitus: A Pivotal, Adaptive, Placebo-Controlled Trial, double blind and with parallel groups.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: IXAKA LIMITED
- Phase: III
- Execution start: 04/04/2022
- End of execution: 30/12/2025
- IP: PABLO PEREZ VALLECILLOS